Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study will:
- Explore whether GA decreases inflammation more on the 3T optimized protocol when
compared to the 1.5T standard protocol.
- Compare whether the decrease in the cumulative number of Gd-enhancing lesions
significantly differs between pre-treatment (day 0) and post-treatment (12 months)
using 1.5T standard and 3T optimized protocols.
- Investigate the correlation between MTR and the cumulative number and volume of Gd
enhancing lesions on 1.5T standard and 3T optimized protocols in patients treated with
GA.
This study suggests that GA may favorably affect early events in lesion formation, in
addition to exerting more transient beneficial effects on established areas of inflammation
and demyelination, and that this effect may be observed only with the 3T optimized protocol.